Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer

BACKGROUND: Bevacizumab is a monoclonal antibody (mAb) against vascular endothelial growth factor (VEGF) and used for treatments of various cancers. Due to the high costs of bevacizumab treatments, a biosimilar provides an affordable alternative therapy for cancer patients. METHODS: In this randomiz...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Transl Lung Cancer Res
Glavni autori: Yang, Yunpeng, Wu, Bin, Huang, Linian, Shi, Meiqi, Liu, Yunpeng, Zhao, Yanqiu, Wang, Lijun, Lu, Shun, Chen, Gongyan, Li, Baolan, Xie, Conghua, Fang, Jian, Yang, Nong, Zhang, Yiping, Cui, Jiuwei, Song, Yong, Zhang, Cuiying, Mei, Xiaodong, Cao, Bangwei, Yang, Lan, Cheng, Ying, Ying, Kejing, Sun, Tao, Ren, Biyong, Yu, Qitao, Liao, Zijun, Pei, Zhidong, Wang, Mengzhao, Zhou, Jianying, Yu, Shiying, Feng, Guosheng, Wan, Huiping, Wang, Huaqing, Gao, Shegan, Wang, Jinliang, An, Guangyu, Geng, Yi, Ji, Yanxia, Yuan, Ying, Ma, Shenglin, Jia, Zhongyao, Hu, Mu, Zhou, Hui, Yu, Jie, Sun, Xing, Zhang, Li
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2019
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6976344/
https://ncbi.nlm.nih.gov/pubmed/32010577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2019.12.23
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items